Global Markets
Home›Global Markets›Trade & Tariffs›China biotech out-licensing hits record as US scrutiny…
China biotech out-licensing hits record as US scrutiny rises
GlobalData said the value of innovative drug out-licensing agreements reached about US$110 billion in the first half of 2026, while US lawmakers pushed a transparency bill aimed at reducing reliance on Chinese medicines and medical technologies.
China’s role as a biotechnology innovation hub has become a strategic concern for US policymakers, prompting a reassessment of how Washington should respond to Beijing’s growing influence, according to analysis cited by the South China Morning Post.
GlobalData healthcare analyst Edita Hamzic said the latest round of Chinese biotech success matters beyond healthcare innovation, with implications for pharmaceutical supply chain resilience, economic competitiveness and national security. She also said the US policy response reflects concerns about competitiveness and technological leadership, not scientific capability alone.
The strength of China’s drug development pipeline has shown up in licensing activity. Figures cited by CCTV, as reported by SCMP, put the value of innovative drug out-licensing agreements at about US$110 billion between January and June 2026, a record high.
SCMP also said Chinese pharmaceutical companies are expanding advanced manufacturing capabilities in specialized areas including high-potency active pharmaceutical ingredients, peptides and small molecules. Earlier this month, US lawmakers introduced legislation aimed at increasing transparency around foreign influence in the pharmaceutical industry, framing it as a first step toward reducing reliance on Chinese medications and medical technologies.